NGL FINECHEM
|
NGL FINECHEM Last 5 Year Financial Ratios History
[Consolidated]
Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
---|---|---|---|---|---|
Operational & Financial Ratios | |||||
Earnings Per Share (Rs) | 33.80 | 66.63 | 33.04 | 80.68 | 91.58 |
CEPS(Rs) | 54.35 | 85.72 | 51.45 | 97.55 | 105.30 |
DPS(Rs) | 1.75 | 1.75 | 1.75 | 1.75 | 1.75 |
Book NAV/Share(Rs) | 457.16 | 425.11 | 360.23 | 328.94 | 250.01 |
Tax Rate(%) | 23.78 | 24.07 | 25.09 | 25.08 | 26.90 |
Margin Ratios | |||||
Core EBITDA Margin(%) | 9.45 | 15.87 | 12.57 | 21.48 | 31.05 |
EBIT Margin(%) | 8.41 | 16.60 | 10.50 | 21.58 | 30.93 |
Pre Tax Margin(%) | 7.53 | 16.07 | 9.84 | 20.98 | 30.08 |
PAT Margin (%) | 5.74 | 12.20 | 7.37 | 15.72 | 21.99 |
Cash Profit Margin (%) | 9.12 | 15.64 | 11.43 | 18.98 | 25.22 |
Performance Ratios | |||||
ROA(%) | 5.36 | 12.86 | 7.27 | 20.61 | 31.42 |
ROE(%) | 7.75 | 17.03 | 9.63 | 27.90 | 44.76 |
ROCE(%) | 9.44 | 20.38 | 11.96 | 33.91 | 53.53 |
Asset Turnover(x) | 0.93 | 1.05 | 0.99 | 1.31 | 1.43 |
Sales/Fixed Asset(x) | 2.02 | 2.36 | 2.07 | 2.82 | 2.75 |
Working Capital/Sales(x) | 3.16 | 2.69 | 2.66 | 2.94 | 3.12 |
Efficiency Ratios | |||||
Fixed Capital/Sales(x) | 0.50 | 0.42 | 0.48 | 0.36 | 0.36 |
Receivable days | 84.83 | 83.78 | 85.22 | 58.36 | 45.10 |
Inventory Days | 46.87 | 37.88 | 54.47 | 53.95 | 46.51 |
Payable days | 106.96 | 85.07 | 75.67 | 72.38 | 78.66 |
Valuation Parameters | |||||
PER(x) | 32.97 | 31.37 | 36.22 | 24.27 | 16.74 |
PCE(x) | 20.51 | 24.38 | 23.26 | 20.07 | 14.56 |
Price/Book(x) | 2.44 | 4.92 | 3.32 | 5.95 | 6.13 |
Yield(%) | 0.16 | 0.08 | 0.15 | 0.09 | 0.11 |
EV/Net Sales(x) | 2.06 | 3.91 | 2.73 | 3.90 | 3.72 |
EV/Core EBITDA(x) | 17.50 | 19.50 | 18.74 | 15.70 | 10.88 |
EV/EBIT(x) | 24.53 | 23.54 | 25.99 | 18.08 | 12.02 |
EV/CE(x) | 2.11 | 4.46 | 2.98 | 4.47 | 4.62 |
M Cap / Sales | 1.87 | 3.81 | 2.66 | 3.81 | 3.67 |
Growth Ratio | |||||
Net Sales Growth(%) | 8.73 | 21.80 | -12.42 | 23.08 | 70.07 |
Core EBITDA Growth(%) | -36.02 | 67.63 | -48.67 | -10.49 | 286.35 |
EBIT Growth(%) | -44.92 | 92.58 | -57.38 | -14.14 | 442.89 |
PAT Growth(%) | -48.87 | 101.58 | -58.92 | -12.03 | 580.47 |
EPS Growth(%) | -49.27 | 101.66 | -59.05 | -11.91 | 597.04 |
Financial Stability Ratios | |||||
Total Debt/Equity(x) | 0.27 | 0.13 | 0.15 | 0.15 | 0.11 |
Current Ratio(x) | 1.98 | 2.46 | 2.79 | 2.64 | 2.98 |
Quick Ratio(x) | 1.55 | 1.96 | 2.33 | 1.79 | 2.08 |
Interest Cover(x) | 9.51 | 31.07 | 15.92 | 35.81 | 36.21 |
Total Debt/Mcap(x) | 0.11 | 0.03 | 0.04 | 0.02 | 0.02 |
Compare Financial Ratios of peers of NGL FINECHEM
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
NGL FINECHEM | ₹872.4 Cr | 3% | 10.1% | -38.9% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹394,187.0 Cr | 0.6% | -2.4% | -7% | Stock Analytics | |
DIVIS LABORATORIES | ₹163,282.0 Cr | -0.3% | -7.6% | 23% | Stock Analytics | |
CIPLA | ₹128,619.0 Cr | 1.8% | 8.1% | -0.1% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹124,712.0 Cr | 0.9% | 3.7% | 8.9% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹106,577.0 Cr | 1% | 2.4% | -9.6% | Stock Analytics |
NGL FINECHEM Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
NGL FINECHEM | 3% |
10.1% |
-38.9% |
SENSEX | 0.9% |
-1.1% |
0.6% |
You may also like the below Video Courses